Alpha-2-macroglobulin mRNA (A2M)

Alpha-2-macroglobulin (A2M) is a massive, multi-functional plasma glycoprotein that serves as a broad-spectrum protease inhibitor, capable of inactivating proteases from all four major classes: serine, cysteine, aspartic, and metalloproteases (UniProt P01023). The A2M mRNA encodes this protein, which utilizes a unique 'trap' mechanism to physically envelop proteases, followed by their rapid clearance from the extracellular space via the LRP1 receptor (Rehman et al., 2013). Beyond its role as a protease scavenger, A2M also binds and modulates the activity of various cytokines and growth factors, such as TGF-beta and TNF-alpha, thereby playing a pivotal role in regulating inflammatory and tissue remodeling processes (NCBI Gene ID: 2). In therapeutic development, A2M is primarily targeted for the treatment of Osteoarthritis (OA), where it acts to inhibit the catabolic enzymes responsible for cartilage degradation, such as MMP-13 and ADAMTS-4/5 (Wang et al., 2014). While current clinical strategies focus on the administration of the A2M protein (e.g., CYT-108) or autologous concentrates, the A2M mRNA represents a potential target for RNA-based therapies aimed at restoring the protease-antiprotease balance in chronic degenerative and neurodegenerative diseases (Cytonics Corp).

Other names

A2MCPAMD5Alpha-2-MS863-7Alpha-2-macroglobulinC3 and PZP-like alpha-2-macroglobulin domain-containing protein 5

Protease trapping and inactivation via a conformational change (Venus flytrap mechanism), followed by LRP1-mediated endocytosis and clearance; modulation of inflammatory cytokines like TNF-alpha and TGF-beta.